The development of persistent GI symptoms in melanoma patients who have had an immune checkpoint inhibitor-related GI toxicity.

In this cohort of melanoma patients who experienced GI-irAE, 26% developed persistent GI symptoms, most frequently constipation. Future studies should characterize the GI sequelae after GI-irAE, which may shed light on DGBI pathogenesis and improve the lives of cancer survivors.